The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2019 | Targeting multiple myeloma antigens

Name: Targeting multiple myeloma antigens
Uploaded: 2019-06-14T00:00:00.000Z
Duration: 2 min 43 s
Description: Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses target antigens in multiple myeloma, namely CD38 and BCMA, and the rationale behind their therapeutic targeting.This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Rakesh Popat • 14 Jun 2019

EHA 2019

Multiple Myeloma

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses target antigens in multiple myeloma, namely CD38 and BCMA, and the rationale behind their therapeutic targeting.This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.